PL2796550T3 - Nowe przeciwciało przeciwko ludzkiemu CTGF - Google Patents

Nowe przeciwciało przeciwko ludzkiemu CTGF

Info

Publication number
PL2796550T3
PL2796550T3 PL12860742T PL12860742T PL2796550T3 PL 2796550 T3 PL2796550 T3 PL 2796550T3 PL 12860742 T PL12860742 T PL 12860742T PL 12860742 T PL12860742 T PL 12860742T PL 2796550 T3 PL2796550 T3 PL 2796550T3
Authority
PL
Poland
Prior art keywords
novel anti
ctgf antibody
human ctgf
human
antibody
Prior art date
Application number
PL12860742T
Other languages
English (en)
Inventor
Shoji Iwasaki
Ryuichi Moriya
Masayasu Yoshino
Koji TAKAKURA
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Publication of PL2796550T3 publication Critical patent/PL2796550T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL12860742T 2011-12-22 2012-12-21 Nowe przeciwciało przeciwko ludzkiemu CTGF PL2796550T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011281811 2011-12-22
EP12860742.1A EP2796550B1 (en) 2011-12-22 2012-12-21 Novel anti-human ctgf antibody
PCT/JP2012/083206 WO2013094723A1 (ja) 2011-12-22 2012-12-21 新規抗ヒトctgf抗体

Publications (1)

Publication Number Publication Date
PL2796550T3 true PL2796550T3 (pl) 2018-08-31

Family

ID=48668601

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12860742T PL2796550T3 (pl) 2011-12-22 2012-12-21 Nowe przeciwciało przeciwko ludzkiemu CTGF

Country Status (16)

Country Link
US (1) US9587015B2 (pl)
EP (1) EP2796550B1 (pl)
JP (1) JP6040943B2 (pl)
KR (1) KR20140107507A (pl)
CN (1) CN104011206B (pl)
AR (1) AR089425A1 (pl)
BR (1) BR112014015405A2 (pl)
CA (1) CA2859627A1 (pl)
EA (1) EA029290B1 (pl)
ES (1) ES2665851T3 (pl)
IN (1) IN2014CN04615A (pl)
MX (1) MX345019B (pl)
PL (1) PL2796550T3 (pl)
PT (1) PT2796550T (pl)
TW (1) TW201333034A (pl)
WO (1) WO2013094723A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109824777A (zh) * 2019-03-15 2019-05-31 辽宁何氏医学院 一种具有抑制玻璃体视网膜纤维化病变作用的单克隆抗体及其制备方法和应用
US20200369759A1 (en) 2019-05-23 2020-11-26 Fibrogen, Inc. Methods of treatment of muscular dystrophies
AU2020289303A1 (en) * 2019-06-04 2022-01-27 Jiangsu Hengrui Medicine Co., Ltd. Anti-connective tissue growth factor antibody and application thereof
US20230416352A1 (en) * 2020-12-03 2023-12-28 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising anti-connective tissue growth factor antibody
JPWO2023238845A1 (pl) 2022-06-07 2023-12-14
WO2024095964A1 (ja) 2022-10-31 2024-05-10 アステラス製薬株式会社 Toll様受容体7/8デュアルアゴニスト化合物を含む抗体薬物複合体
CN120858112A (zh) * 2023-03-10 2025-10-28 江西康莱特新森医药原料有限公司 一种靶向ctgf的抗体或其抗原结合片段及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE8808645U1 (de) 1988-07-06 1988-08-25 Hofer, Daniel, 7730 Villingen-Schwenningen Anzeigeeinrichtung für Feuerlöscher
US6114143A (en) 1993-03-11 2000-09-05 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Anti-HIV monoclonal antibody
JP4537507B2 (ja) 1997-12-25 2010-09-01 アムジェン インコーポレイテッド 結合組織増殖因子に対するモノクローナル抗体及びその医薬用途
AU1682699A (en) 1997-12-25 1999-07-19 Japan Tobacco Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
EP1140964B1 (en) 1998-12-14 2008-04-09 University Of Miami Connective tissue growth factor (ctgf) fragment
US7115390B1 (en) 1998-12-14 2006-10-03 Fibrogen, Inc. Connective tissue growth factor fragments and methods and uses thereof
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7405274B2 (en) 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
JP2009067678A (ja) * 2005-12-07 2009-04-02 Nihon Nosan Kogyo Kk 結合組織増殖因子に対する抗体又はそれを含む組成物
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor

Also Published As

Publication number Publication date
JPWO2013094723A1 (ja) 2015-04-27
KR20140107507A (ko) 2014-09-04
AR089425A1 (es) 2014-08-20
MX2014007681A (es) 2014-11-25
EP2796550A1 (en) 2014-10-29
US9587015B2 (en) 2017-03-07
PT2796550T (pt) 2018-04-18
EA029290B1 (ru) 2018-03-30
ES2665851T3 (es) 2018-04-27
CN104011206A (zh) 2014-08-27
BR112014015405A2 (pt) 2017-06-13
IN2014CN04615A (pl) 2015-09-18
JP6040943B2 (ja) 2016-12-07
EP2796550B1 (en) 2018-02-28
EA201491240A1 (ru) 2014-11-28
EP2796550A4 (en) 2015-08-19
CN104011206B (zh) 2017-03-08
TW201333034A (zh) 2013-08-16
US20140343258A1 (en) 2014-11-20
WO2013094723A1 (ja) 2013-06-27
MX345019B (es) 2017-01-11
CA2859627A1 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
IL259826A (en) Anti-alphabetatisiar antibody
ZA201400768B (en) Interleukin-31 monoclonal antibody
ZA201307983B (en) Anti-b7-h3 antibody
IL220404A (en) Antiseptic antibodies
GB201103955D0 (en) Antibodies
GB201112056D0 (en) Antibodies
ZA201400741B (en) Novel anti-human ngf antibody
TWI563004B (en) Anti-hxcr1 antibody
PT2695897T (pt) Novo anticorpo anti-receptor de il-23 humano
PL2796550T3 (pl) Nowe przeciwciało przeciwko ludzkiemu CTGF
EP2694539A4 (en) POLYCLONAL ANTIBODY COMPOSITIONS
EP2707392A4 (en) MONOCLONAL ANTIBODY FOR ACETYLAMANTADINE
EP2821416A4 (en) NEW ANTI-RECEPTOR ANTIBODY IL-23 HUMAN
EP2714074A4 (en) ANTIBODIES AGAINST EMR1